Therapy News and Research

RSS

Sequana Medical's ALFApump System for liver cirrhosis receives CE Mark approval

Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System.

13 Jul 2011

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

13 Jul 2011

Blood cancer drug trial results questioned by FDA

U.S. drug reviewers might limit the use of a Seattle Genetics Inc’s experimental blood cancer drug due to the narrow scope of its clinical trials. According to papers released Tuesday by the Food and Drug Administration (FDA), it requests an advisory panel to consider the drug, under the proposed trade name Adcetris known chemically as brentuximab vedotin, for use in previously treated patients with Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL).

13 Jul 2011

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

St. Jude Medical, Inc., a global medical device company, today announced the U.S. Food and Drug Administration (FDA) clearance and limited market release of the Epiducer lead delivery system for neurostimulation therapy.

13 Jul 2011

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor.

13 Jul 2011

UNC receives $32 million federal grant to eradicate HIV infection

Researchers at the University of North Carolina at Chapel Hill have been awarded a $32 million, five-year federal grant to develop ways to cure people with HIV by purging the virus hiding in the immune systems of patients taking antiretroviral therapy.

12 Jul 2011

Researchers find clear changes in how emotions are processed in smokers

A team of researchers led by the University of Bonn found clear changes in how emotions are processed in smokers. After an abstinence period of 12 hours, the brain's fear center was mostly out of commission in addicts.

12 Jul 2011

New research strategy for eradicating HIV from the body

An international team led by researchers from the University of California, San Francisco and the nonprofit Vaccine and Gene Therapy Institute of Port St. Lucie, Fla., has received a major grant from the National Institutes of Health to develop a strategy to eradicate HIV from the body.

12 Jul 2011

Two studies on childhood leukemia

A difficult-to-treat form of childhood leukemia relies on changes in the structure of DNA - so-called epigenetic changes - to wreak genomic havoc within white blood cells, according to one of two studies conducted by a research team at Children's Hospital Boston and Dana-Farber Cancer Institute.

12 Jul 2011

Two papers highlight therapeutic potential of human Sertoli cells

Two papers published in the current issue of Cell Transplantation, now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, highlight the therapeutic potential of human Sertoli cells that are present in the testes and are also called "nurse" or "mother" cells because they nurture the developing sperm cells.

12 Jul 2011

Gilead announces expansion of global access program for HIV medications

Gilead Sciences, Inc. announced today an expansion of its global access program in an effort to provide accelerated access to Gilead medicines for the treatment of HIV/AIDS.

12 Jul 2011

Groundbreaking study on treatment of separation anxiety disorder

A group of Swiss researchers headed by Prof. Sylvia Schneider has published a groundbreaking study on treatment of separation anxiety in the current issue of Psychotherapy and Psychosomatics.

12 Jul 2011

Wisdom psychology offers an approach to treat PTED

In the current issue of Psychotherapy and Psychosomatics Prof. Michael Linden and collaborators at the University of Berlin present the first randomized controlled trial on a new approach based on wisdom psychology and hedonia strategies.

12 Jul 2011

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

genOway and bluebird bio report today genOway acquisition of an exclusive worldwide license for the RMCE technology (developed at the Massachusetts Institute of Technology) in the field of genetically modified rodents.

12 Jul 2011

AACR Conference on Frontiers in Basic Cancer Research to be held in San Francisco

For more than 100 years, the American Association for Cancer Research has been the premier leader in the basic science of cancer research.

12 Jul 2011

FDA approves protocol for Medtronic's SYMPLICITY HTN-3 for treatment of hypertension

Medtronic, Inc., announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the company's U.S. clinical trial of renal denervation with the Symplicity Catheter System for the treatment of resistant hypertension, an especially dangerous disease affecting hundreds of millions of people worldwide.

From Medtronic 12 Jul 2011

Hutchinson Center receives $20M NIH grant to eradicate HIV infection

Whether a stem cell transplant using an HIV-infected person's own genetically modified immune cells can become a cure for the disease is the focus of a new $20 million, five-year research grant award announced today by the National Institutes of Health to Fred Hutchinson Cancer Research Center.

12 Jul 2011

Federal funds may help Gladstone to solve problem of HIV latency

The Gladstone Institutes will receive funds totaling $5.6 million over five years as part of the first-ever major funding initiative focusing on HIV eradication.

12 Jul 2011

Virtual and physical reality exercises can increase movement speeds in Parkinson's patients

In people with Parkinson's Disease (PD), the inability to make quick movements limits basic functioning in daily life. Movement can be improved by various cueing techniques, such as providing visual or auditory stimuli when movements are started. In a study scheduled for publication in the August issue of the Archives of Physical Medicine and Rehabilitation, researchers report that virtual reality (VR) and physical reality exercises can be used to provide effective stimuli to increase movement speeds in PD patients.

11 Jul 2011

NIAID awards $14 million a year for new HIV research

Three research teams focused on developing strategies that could help to rid the body of HIV are receiving grants totaling more than $14 million a year, for up to five years, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announced today.

11 Jul 2011